Chemistry:AZ-11713908
From HandWiki
Short description: Chemical compound
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C27H32N4O3S2 |
| Molar mass | 524.70 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) | |
AZ-11713908 is a drug developed by AstraZeneca which is a peripherally selective cannabinoid agonist, acting as a potent agonist at the CB1 receptor and a partial agonist at CB2. It has poor blood–brain barrier penetration, and so while it is an effective analgesic in animal tests, it produces only peripheral effects at low doses, with much weaker symptoms of central effects compared to other cannabinoid drugs such as WIN 55,212-2.[1] Many related benzimidazole-derived cannabinoid ligands are known.[2][3][4][5]
See also
References
- ↑ "A peripherally restricted cannabinoid receptor agonist produces robust anti-nociceptive effects in rodent models of inflammatory and neuropathic pain". Pain 151 (2): 337–44. November 2010. doi:10.1016/j.pain.2010.07.019. PMID 20696525.
- ↑ "5-Sulfonyl-benzimidazoles as selective CB2 agonists". Bioorganic & Medicinal Chemistry Letters 18 (8): 2574–9. April 2008. doi:10.1016/j.bmcl.2008.03.048. PMID 18394887.
- ↑ "Novel benzimidazole derivatives as selective CB2 agonists". Bioorganic & Medicinal Chemistry Letters 18 (13): 3695–700. July 2008. doi:10.1016/j.bmcl.2008.05.073. PMID 18522867.
- ↑ WO patent 2004/108688, LIU Z, PAGÈ D, WALPOLE C, YANG H, "BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF", granted 16.12.2004
- ↑ WO patent 2004/108712, LIU Z, PAGÈ D, WALPOLE C, YANG H, "BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF", granted 16.12.2004
 |  |
